1
|
Li X, Li Y, Yu H, Men LL, Deng G, Liu Z, Du JL. Oxidized LDL decreases the survival of bone marrow stem cells via inhibition of Bcl-2 expression. Tissue Eng Part A 2024. [PMID: 38818810 DOI: 10.1089/ten.tea.2024.0025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2024] Open
Abstract
Therapy with mesenchymal stem cells (MSCs) is considered an attractive strategy for the repair or regeneration of damaged tissues. However, low survival of MSCs limits their applications clinically. Oxidized low-density lipoprotein (ox-LDL) is significantly increased in patients with hyperlipidemia and decreases the survival of MSCs. Bcl-2 is critically involved in important cell functions including cell membrane integrity and cell survival. The present study was designed to test the hypothesis that ox-LDL attenuate the survival of MSCs via suppression of Bcl-2 expression. Bone marrow MSCs from C57BL/6 mice were cultured with ox-LDL at different concentrations (0-140 μg/ml) for 24 hours with native LDL as control. Ox-LDL treatment substantially decreased the survival of MSCs dose-dependently and enhanced the release of intracellular LDH in association with a significant decrease in Bcl-2 protein level without change in BAX protein expression in MSCs. Bcl-2 overexpression effectively protected MSCs against ox-LDL-induced damages with preserved cell numbers without significant increase in LDH release. Treatment with N-acetylcysteine (NAC) (1 mM) effectively preserved Bcl-2 protein expression in MSCs and significantly attenuated ox-LDL-induced decrease of cell number and increase in the release of intracellular LDH. These data indicated that ox-LDL treatment resulted in a significant damage of cell membrane and dramatically decreased the survival of MSCs dose-dependently through inhibition of Bcl-2 expression. NAC treatment significantly protected MSCs against the damage of cell membrane by ox-LDL and promoted the survival of MSCs in association with preserved Bcl-2 expression.
Collapse
Affiliation(s)
- Xin Li
- First Affiliated Hospital of Dalian Medical University, Department of Endocrinology, Dalian, Liaoning, China
- Ningbo No 2 Hospital, Department of Endocrinology, Ningbo, Zhejiang, China;
| | - Yu Li
- First Affiliated Hospital of Dalian Medical University, Department of Endocrinology, Dalian, Liaoning, China;
| | - Hao Yu
- First Affiliated Hospital of Dalian Medical University, Department of Endocrinology, Dalian, Liaoning, China;
| | - Li-Li Men
- First Affiliated Hospital of Dalian Medical University, Department of Endocrinology, Dalian, Liaoning, China;
| | - Glenn Deng
- Ningbo No 2 Hospital, Research Center for Single-Cell Omics and Personalized Medicine, Ningbo, Zhejiang, China;
| | - Zhenguo Liu
- University of Missouri School of Medicine, Center for Precision Medicine and Division of Cardiovascular Medicine, Department of Medicine, Columbia, Missouri, United States;
| | - Jian-Ling Du
- First Affiliated Hospital of Dalian Medical University, Department of Endocrinology, Dalian, Liaoning, China;
| |
Collapse
|
2
|
Chang P, Zhang M, Zhang X, Li G, Hu H, Wu J, Wang X, Yang Z, Zhang J, Chen W, Ren M, Li X, Zhu M, Chen B, Yu J. B-type natriuretic peptide attenuates endoplasmic reticulum stress in H9c2 cardiomyocytes underwent hypoxia/reoxygenation injury under high glucose/high fat conditions. Peptides 2019; 111:103-111. [PMID: 29689346 DOI: 10.1016/j.peptides.2018.04.016] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/17/2017] [Revised: 04/17/2018] [Accepted: 04/19/2018] [Indexed: 02/06/2023]
Abstract
Exogenously administered B-type natriuretic peptide (BNP) has been shown to provide cardioprotection against various heart diseases. However, the underlying mechanisms remain elusive. This study explores whether BNP exerts its cardioprotection against hypoxia/reoxygenation (H/R) injury under high glucose/high fat (HG/HF) conditions in cardiac H9c2 cells and uncovers the underlying mechanisms. Our data revealed that BNP significantly increased the cell viability and decreased the release of lactate dehydrogenase (LDH) and creatine kinase (CK), with a maximal effect at the BNP concentration of 10-7 mol/L. In addition, by analyzing the activation of cleaved caspase-3 and by Annexin V-FITC/PI staining, we showed that BNP attenuated H/R-induced cell apoptosis in HG/HF conditions. Western blot analysis showed enhanced phosphorylation of protein kinase RNA (PKR)-like endoplastmic reticulum (ER) kinase (PERK) and eukaryotic initiation factor 2α (eIF2α)(one of the three main signaling pathways in endoplastmic reticulum (ER) stress), and increased expression of GRP78 and CHOP proteins (ER stress-related proteins) in H9c2 cells which underwent H/R in HG/HF conditions. Treatment with BNP or 8-Br-cGMP (an analog of cGMP) reversed this activation. However, this effect was significantly weakened by KT-5823, a selective cGMP-dependent protein kinase G (PKG) inhibitor. In addition, similar to BNP, treatment with a specific inhibitor of ER stress tauroursodeoxycholic acid (TUDCA) protected the cells against H/R injury exposed to HG/HF conditions. In conclusion, these findings demonstrated that BNP effectively protected cells against H/R injury under HG/HF conditions by inhibiting the ER stress via activation of the cGMP-PKG signaling pathway.
Collapse
Affiliation(s)
- Pan Chang
- Shaanxi Key Laboratory of Ischemic Cardiovascular Disease, Xi'an Medical University, Xi'an, China; Department of Cardiology, Second Affiliated Hospital, Xi'an Medical University, Xi'an, China; Department of Physiology, Fourth Military Medical University, Xi'an, China
| | - Mingyang Zhang
- Institute of Forensic Sciences, Soochow University, Suzhou, China
| | - Xiaomeng Zhang
- Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi'an, China
| | - Guohua Li
- Department of Physiology, Fourth Military Medical University, Xi'an, China
| | - Haiyan Hu
- Department of Cardiology, Second Affiliated Hospital, Xi'an Medical University, Xi'an, China
| | - Juan Wu
- Department of General Practitioner, Second Affiliated Hospital, Xi'an Medical University, Xi'an, China
| | - Xihui Wang
- Department of Cardiology, Second Affiliated Hospital, Xi'an Medical University, Xi'an, China
| | - Zihua Yang
- Department of Hepatobiliary Surgery, Second Affiliated Hospital, Xi'an Medical University, Xi'an, China
| | - Jing Zhang
- Department of Cardiology, Second Affiliated Hospital, Xi'an Medical University, Xi'an, China
| | - Weiguo Chen
- Department of General Practitioner, Second Affiliated Hospital, Xi'an Medical University, Xi'an, China
| | - Minggang Ren
- Department of Cardiology, Second Affiliated Hospital, Xi'an Medical University, Xi'an, China
| | - Xin Li
- Department of Cardiology, Second Affiliated Hospital, Xi'an Medical University, Xi'an, China
| | - Miaozhang Zhu
- Department of Physiology, Fourth Military Medical University, Xi'an, China.
| | - Baoying Chen
- Department of Radiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
| | - Jun Yu
- Shaanxi Key Laboratory of Ischemic Cardiovascular Disease, Xi'an Medical University, Xi'an, China; Department of Cardiology, Second Affiliated Hospital, Xi'an Medical University, Xi'an, China.
| |
Collapse
|
3
|
Natriuretic peptide receptor guanylyl cyclase-A pathway counteracts glomerular injury evoked by aldosterone through p38 mitogen-activated protein kinase inhibition. Sci Rep 2017; 7:46624. [PMID: 28429785 PMCID: PMC5399490 DOI: 10.1038/srep46624] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2016] [Accepted: 03/22/2017] [Indexed: 12/11/2022] Open
Abstract
Guanylyl cyclase-A (GC-A) signaling, a natriuretic peptide receptor, exerts renoprotective effects by stimulating natriuresis and reducing blood pressure. Previously we demonstrated massive albuminuria with hypertension in uninephrectomized, aldosterone-infused, and high salt-fed (ALDO) systemic GC-A KO mice with enhanced phosphorylation of p38 mitogen-activated protein kinase (MAPK) in podocytes. In the present study, we examined the interaction between p38 MAPK and GC-A signaling. The administration of FR167653, p38 MAPK inhibitor, reduced systolic blood pressure (SBP), urinary albumin excretion, segmental sclerosis, podocyte injury, and apoptosis. To further investigate the local action of natriuretic peptide and p38 MAPK in podocytes, we generated podocyte-specific (pod) GC-A conditional KO (cKO) mice. ALDO pod GC-A cKO mice demonstrated increased urinary albumin excretion with marked mesangial expansion, podocyte injury and apoptosis, but without blood pressure elevation. FR167653 also suppressed urinary albumin excretion without reducing SBP. Finally, we revealed that atrial natriuretic peptide increased phosphorylation of MAPK phosphatase-1 (MKP-1) concomitant with inhibited phosphorylation of p38 MAPK in response to MAPK kinase 3 activation, thereby resulting in decreased mRNA expression of the apoptosis-related gene, Bax, and Bax/Bcl2 ratio in cultured podocytes. These results indicate that natriuretic peptide exerts a renoprotective effect via inhibiting phosphorylation of p38 MAPK in podocytes.
Collapse
|
4
|
Røsjø H, Omland T. B-Type Natriuretic Peptide as a Therapeutic Strategy: Opportunities and Pitfalls. Cardiology 2015; 133:119-21. [PMID: 26523893 DOI: 10.1159/000441138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/17/2015] [Accepted: 09/17/2015] [Indexed: 11/19/2022]
Affiliation(s)
- Helge Røsjø
- Division of Medicine, Akershus University Hospital, Lx00F8;renskog, and Center for Heart Failure Research and K.G. Jebsen Cardiac Research Centre, University of Oslo, Oslo, Norway
| | | |
Collapse
|